Bruker Corporation (BRKR)
BRKR trades on Nasdaq in Industrials, Biotechnology: Laboratory Analytical Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1109354/000119312526082523/0001193125-26-082523-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BRKR on Nasdaq |
| Sector | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001109354 |
| SEC industry code | Laboratory Analytical Instruments |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.4B |
| Net income | -$8.6M |
| Operating income | $68.2M |
| Net margin | -0.3% |
| Operating margin | 2.0% |
| Revenue growth | +2.1% |
| Cash | $298.8M |
| Total assets | $6.2B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $119.7M cash; operating cash flow $85.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 152,722,385 (2026-11-02); 151,941,144 a year earlier; 138,411,212 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-06-12 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $3.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $874.0M | -$111.8M | $118.2M | $119.7M | $1.7B | $3.5B | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $838.5M | -$52.0M | -$77.4M | $184.9M | $1.8B | $3.5B | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $823.4M | $14.4M | $71.2M | $133.4M | $1.7B | $3.5B | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $977.2M | $26.0M | $229.8M | $298.8M | $1.9B | $3.4B | 10-K 2026-02-27 |
| Q3 2025 2025-09-30 | $860.5M | -$59.6M | -$33.2M | $293.1M | $2.0B | $3.4B | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $797.4M | $7.6M | -$127.5M | $92.0M | $2.4B | $3.4B | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $801.4M | $17.4M | $65.0M | $184.2M | $2.1B | $3.4B | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $979.6M | $13.7M | $190.0M | $183.4M | $2.1B | $3.4B | 10-K 2026-02-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-06-12 |
| Latest annual report | 10-K | 2026-02-27 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-04-10 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.5% |
| 1 month | +9.6% |
| 3 months | +6.3% |
| Year to date | +30.7% |
| 1 year | +47.4% |
| From 52-week high | -7.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| BRKRP | Bruker Corporation 6.375% Mandatory Convertible Preferred Stock Series A | $439.63 |
Peers in Biotechnology: Laboratory Analytical Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BIO | Bio-Rad Laboratories Inc. | $360.26 | -1.67% | $9.7B |
| AVTR | Avantor Inc. | $15.32 | -1.42% | $10.4B |
| TXG | 10x Genomics Inc. | $54.99 | -5.50% | $7.2B |
| RVTY | Revvity Inc. | $148.85 | -3.59% | $16.6B |
| MTD | Mettler-Toledo International Inc. | $1727.26 | -0.67% | $34.4B |
| ALMR | Alamar Biosciences Inc. | $30.55 | -0.84% | $2.1B |
| WAT | Waters Corporation | $453.42 | -1.48% | $44.6B |
| A | Agilent Technologies Inc. | $172.92 | -0.60% | $48.8B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier